MRK ▼ -0.9% - Merck & Co., Inc.
$MRK MRNA - Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
22-OCT-2026 03:06 PM ET
Share this post
More filings for $MRK
MRK ▲ +1.2% - Merck & Co., Inc.Nov 9, 2026MRK ▲ +0.9% - Merck & Co., Inc.Nov 9, 2026MRK ▼ -0.5% - Merck & Co., Inc.Nov 3, 2026MRK ▲ +2.8% - Merck & Co., Inc.Oct 29, 2026MRK ▼ -2.4% - Merck & Co., Inc.Oct 26, 2026MRK ▼ -1.9% - Merck & Co., Inc.Oct 23, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment